Russell Conley: 2024 will be a period of immense growth for the AGITG and GI Cancer Institute with the launch of our own clinical trial coordinating centre

Russell Conley, Chief Executive Officer at GI Cancer Institute, shared a post by GI Cancer Institute & Australasian Gastro-Intestinal Trials Group on LinkedIn, adding the following:

“2024 will be a period of immense growth for the AGITG and GI Cancer Institute with the launch of our own clinical trial coordinating centre, which has been several years in the planning and an output of our current Strategic Plan.
Greater control of processes across clinical trial coordination will result in myriad efficiencies and build upon our expertise in clinical trial design developed over 30+ years.
This year we will activate four internally coordinated clinical trials including Neo-POLEM in collaboration with Imugene and University of Southhampton.
We are grateful for all the outstanding work of our team of talented staff and clinician researchers, working together to improve treatments for patients with gastrointestinal cancers.
Thank you to all those who support our research.
We look forward to sharing news of our progress and achievements in the year ahead.”

Quoting GI Cancer Institute & Australasian Gastro-Intestinal Trials Group:

“We are thrilled to be the local Australian sponsor of this important study. It will also be the second trial coordinated by the AGITG clinical trials team. We look forward to opening the Neo-POLEM clinical trial in 2024.”

Source: Russell Conley/LinkedIn and GI Cancer Institute & Australasian Gastro-Intestinal Trials Group/LinkedIn